Contact
searchSearch
HMP Global
Login

EZH2 News

News
Novel, Minimally Invasive Test Detects Higher Frequency of EZH2 Mutations in Follicular Lymphoma
11/14/2022
Parallel testing of both tissue and liquid biopsy samples detects a higher frequency of EZH2 mutations in patients with follicular lymphoma, with significant clinical implications, according to a recent study.
Parallel testing of both tissue and liquid biopsy samples detects a higher frequency of EZH2 mutations in patients with follicular lymphoma, with significant clinical implications, according to a recent study.
Parallel testing of both tissue...
11/14/2022
Oncology
News
Tazemetostat Reduces EZH2 Activity in Patients with Malignant Mesothelioma
07/06/2022
Findings from an open-label phase 2 study reveal treatment with tazemetostat reduces EZH2 activity and B-cell infiltration in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.
Findings from an open-label phase 2 study reveal treatment with tazemetostat reduces EZH2 activity and B-cell infiltration in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.
Findings from an open-label...
07/06/2022
Oncology
News
Valemetostat Shows Superiority in Patients With DLBCL
03/16/2022
Valemetostat shows efficacy for patients with DLBCL and greater EZH2-specific inhibition effects compared to current regimens.
Valemetostat shows efficacy for patients with DLBCL and greater EZH2-specific inhibition effects compared to current regimens.
Valemetostat shows efficacy for...
03/16/2022
Oncology
News
New Therapeutic Target Found for EZH2 Mutant Hematologic Malignancies
02/25/2022
A novel therapeutic target for mutant EZH2 expression in DLBCL and AML was discovered with feasibility to overcome resistance to current inhibitors.
A novel therapeutic target for mutant EZH2 expression in DLBCL and AML was discovered with feasibility to overcome resistance to current inhibitors.
A novel therapeutic target for...
02/25/2022
Oncology
News
Tazemetostat Shows Meaningful Response Rates in R/R FL
02/22/2022
Phase 2 trial results of tazemetostat demonstrate encouraging efficacy in patients with R/R EZH2 mutant FL.
Phase 2 trial results of tazemetostat demonstrate encouraging efficacy in patients with R/R EZH2 mutant FL.
Phase 2 trial results of...
02/22/2022
Oncology
News
EZH2 Inhibitor Valemetostat Shows Antitumor Effect in Hematologic Malignancies
02/03/2022
Primary analysis results of the EZH2 inhibitor valemetostat reveal antitumor activity against the development and progression of R/R ATL, presented at ASH 2021.
Primary analysis results of the EZH2 inhibitor valemetostat reveal antitumor activity against the development and progression of R/R ATL, presented at ASH 2021.
Primary analysis results of the...
02/03/2022
Oncology
News
Tazemetostat Safe, Effective for Relapsed/Refractory Malignant Mesothelioma
07/28/2020
In a phase 2 study, tazemetostat was well-tolerated and demonstrated anti-tumor activity in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
In a phase 2 study, tazemetostat was well-tolerated and demonstrated anti-tumor activity in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
In a phase 2 study, tazemetostat...
07/28/2020
Oncology
News
FDA Approves Tazemetostat for Relapsed/Refractory FL
06/18/2020
The FDA granted accelerated approval to tazemetostat for adult patients with confirmed EZH2-positive relapsed/refractory FL who have received at least 2 prior systemic therapies.
The FDA granted accelerated approval to tazemetostat for adult patients with confirmed EZH2-positive relapsed/refractory FL who have received at least 2 prior systemic therapies.
The FDA granted accelerated...
06/18/2020
Oncology
News
EZH2 Inhibitor Safe, Active in Relapsed/Refractory FL
04/20/2020
Tazemetostat was shown to be active in patients with FL in a phase 2 study, and yielded a low incidence of treatment-related AEs.
Tazemetostat was shown to be active in patients with FL in a phase 2 study, and yielded a low incidence of treatment-related AEs.
Tazemetostat was shown to be...
04/20/2020
Oncology
News
Tazemetostat Shows Promise in Refractory B-Cell NHL and Advanced Solid Tumors
08/17/2018
Tazemetostat therapy yields favorable safety and antitumor activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumors.
Tazemetostat therapy yields favorable safety and antitumor activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumors.
Tazemetostat therapy yields...
08/17/2018
Oncology

Recent News

News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use